The biochemistry of rapid replication
Replikins Logo

home
right
right
right
right
right
right
right
home

 

44. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals November 10, 2011


LONDON, Nov. 10, 2011 -- Animals and humans no longer need to be "sitting ducks," oblivious to and unprepared for emergent infectious disease outbreaks. Rather than being caught off-guard by mass influenza outbreaks, UK-based biotech firm BioRadar Ltd. can successfully analyze the concentration and structure of the genomic Replikins in 'scout' viruses isolated from initial cases up to one year or longer, which provides advance warning of, and the ability to respond to the coming specific outbreaks (1,2).

(The standard deviation of the mean (SD) indicates the population distribution of viruses with different Replikin Counts. At relatively low virus replication rates, the SD is small; the SD of the Replikin Counts increases with virus rapid replication, and an increase in the Mean follows (2).)

More significantly, the advance warning affords BioRadar the time to produce specific solid-phase synthetic Replikins vaccines in seven days, and to test them thoroughly. Bulk production also takes days rather than months. Storage does not require refrigeration. For an example of current advance warning in H5N1 influenza, see Figure. Specifically, BioRadar UK Ltd will make available the following synthetic updated Bogoch Replikins vaccines for animals: ReplikinsTransFluT against H5N1-H9N2-H1N1 Influenza Viruses in Poultry; ReplikinsFMDT against Foot and Mouth Disease Virus in Livestock; ReplikinsTauraT against Taura Syndrome Virus in Shrimp; and ReplikinsAMDT against Aleutian Mink Disease Virus in mink.

BioRadar UK Ltd. has identified the specific Replikins in the H5N1 virus genome, both conserved and novel, which are currently building in concentration, increasing the risk of large outbreaks of H5N1 (Figure; Ref 3). The current H5N1 buildup, beginning in 2007 in birds, earlier in humans, resembles the Replikins buildup which led to the prediction in 2008 of the 2009 H1N1 Pandemic, one year in advance (1,2). Initial H5N1 and H1N1 cases are now occurring (7,8) and have led to the formulation of Synthetic Replikins Updated TransFluT Vaccines.

When the Replikins change again, the vaccine can be changed in 7 days. The 'Two Punch' (against more than one gene) Replikins TransFluT vaccine has been proven effective against H5N1 in chickens and totally blocked virus excretion, making control of virus reservoirs possible (4).

In the previous H5N1 outbreaks between 1997 and 2011, the predictions published one year in advance, based on increases in Replikin CountT, have been followed invariably by strain-specific virus outbreaks (5-8). In the Foot and Mouth Disease (FMD) virus genome, BioRadar identified both conserved (back to 1964) and new Replikins. In 2009, FMD genomic Replikins increased in concentration to their highest level in 52 years and thus predicted, one year in advance (6), the current 2010-2011 outbreaks of FMD.

Conclusions:

  1. The new technology of the Replikins chemistry of the genome of pathogens makes accurate predictions of strain-specific outbreaks possible for the first time.
  2. For each pathogen, the specific genomic Replikins are the basis for the specific Replikins Synthetic Vaccines.
  3. When the genomic Replikins change, the vaccine can be changed in 7 days, providing ReplikinsUpdatedVaccinesT.

The UN Food and Agriculture Organization (UN FAO) has noted the accuracy of Replikin CountT predictions (8), and the UK Department of Trade and Investment has green-lighted BioRadar UK Ltd. (9).

To receive product update information, e-mail to Vaccines@Replikins.com
Name ______________________ Company or Institution ______________________
Address ______________________ Country ______________________
e-mail ______________________ Telephone number ______________________
For price quotes , specify animal vaccine and indicate number of units required

  Number of units :
  (One unit = 100,000 doses of vaccine)
ReplikinsPanFluT Vaccine (__)
Replikins FMDT Vaccine (__)
AquaReplikinsTauraT Vaccine (__)
ReplikinsAMDT Vaccine (__)

References:

  1. Replikins Press. Report No. 18. H1N1 Influenza Virus with Highest Replikin CountT Since the 1918 Pandemic Identified in the U.S. and Austria (April 7, 2008) Replikins
  2. Bogoch, Samuel and Bogoch, Elenore. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins . Available from Nature Precedings http://dx.doi.org/10.1038/npre.2011.6279.1 (2011)"
  3. Bogoch, Samuel and Bogoch, Elenore. Marked Rise in Replikin Counts in H5N1 Influenza Virus Localized to p B1. Available from Nature Precedings http://dx.doi.org/10.1038/npre.2011.6420.1 (2011)
  4. Jackwood MW, Bogoch, S., Bogoch ES, Hilt, D and Williams SW. Efficacy of a Replikin peptide Vaccine Against Low Pathogenicity Avian Influenza H5 Virus . Avian Diseases 53(4):613-617, 2009.
  5. Replikins Press Reports, Nos. 1-43, 2006-2011 Replikins
  6. Replikins Press Reports, No. 37. Current Severe Outbreaks of Foot and Mouth Disease Predicted by Replikins' BioRadarT One Year in Advance (June 2009) Replikins
  7. Replikins Press Reports, No. 36. Both H5N1 Bird Flu and H1N1 Swine Flu Replikin CountsT Increasing. April 9, 2010 Replikins
  8. Replikins Press Reports, No. 43. DVM Newsmagazine, UN Food and Agriculture Organization (FAO) discussion of Replikins. September 8, 2011 Replikins
  9. Replikins Press Reports, No. 35. UK Trade and Investment article. BioRadar to set up HQ in Britain . March 25, 2010 Replikins

SOURCE BioRadar Ltd.
CONTACT: +1-646-320-5910, vaccines@replikins.com



Learn more  

Dr. Sanjay Gupta of CNN reports on Replikins

Synthetic flu vaccine option?

2009 report on Replikins and the potential of synthetic vaccine technology to improve on traditional vaccine approaches.

 

The Science:
Replikins in H1N1

Hemagglutinin

A recent Nature Precedings paper shows the location of Replikins peptides on the surface of the active Hemagglutinin portion of the H1N1 virus.